How one father built a biotech, Grace Science, to save his daughter
Highlights Matt Wilsey has spent a decade and $70 million trying to develop a cure for his daughter…
AstraZeneca, Ionis report major trial failure with heart disease drug
Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially…
Anthropic releases Claude Science, sees Claude Code level impact
Brittany Trang, Ph.D., covers AI in health and medicine: Does it actually work? Who benefits, or might be…
Abivax aims to ease safety concerns with new ulcerative colitis data
Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially…
China, Shanghai, AI hair growth drug, Eli Lilly: Readout Newsletter
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter…
Definium LSD therapy for major depression helped patients in Phase 3 trial
Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected…
Recursion Pharmaceuticals vs. Schrödinger: Which Healthcare Stock Is a Better Buy in 2026?
As drug discovery moves from trial-and-error to digital simulation, choosing between Recursion Pharmaceuticals (NASDAQ:RXRX) and Schrödinger (NASDAQ:SDGR) depends…
Breakthrough in cancer immunotherapy: Promising therapy for advanced solid tumours
Image: © koto_feja | iStock As part of a clinical study, the Early Clinical Trial Unit (ECTU) at…
Industry and regulators signal a smarter, collaborative era for supplement oversight
While the industry has spent years bracing for and fending off a heavier regulatory hand, what it heard…
AI helps create miniprotein switches for drug targets
image: ©whitehoun | iStock The UW Medicine Institute for Protein Design and Skape Bio have led a new…
Medicare spending far less than expected on new Alzheimer’s drugs
Bob Herman covers health insurance, government programs, hospitals, physicians, and other providers — reporting on how money influences…
3 Stocks Poised to Disrupt the Healthcare Market by 2030
The biggest mistake investors make with healthcare stocks is assuming the future will look like the past: incremental…